NCT00813163View on ClinicalTrials.gov

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

July 31, 2012

Conditions
Pancreatic Neoplasms
Interventions
DRUG

PEP02

"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."

Trial Locations (3)

100

National Taiwan University Hospital, Taipei

704

National Health Research Institutes/National Chen-Kung Uiversity Hospital, Tainan City

94115

Comprehensive Cancer Center, UCSF, San Francisco

Sponsors

Lead Sponsor

PharmaEngine
All Listed Sponsors
lead

PharmaEngine

INDUSTRY

NCT00813163 - Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter